Emtricitabine And Tenofovir Disoproxil Fumarate Tablet
Product Images NDC 42543-719

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Emtricitabine And Tenofovir Disoproxil Fumarate (NDC 42543-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Strides Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (5222ff1f 65db 4944 859c 2dc73afb9d83 01)

Chemical structure diagram of the active ingredient Emtricitabine from the Emtricitabine and Tenofovir Disoproxil Fumarate tablet by Strides Pharma Inc. The structure shows atoms and bonds typical of the molecule's composition.*

FDA Label Image

Structure (5222ff1f 65db 4944 859c 2dc73afb9d83 02)

Chemical structure diagram depicting Emtricitabine and Tenofovir Disoproxil Fumarate, the active ingredients in the oral tablet formulation by Strides Pharma Inc.*

FDA Label Image

Container (5222ff1f 65db 4944 859c 2dc73afb9d83 03)

Label for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg / 300 mg by Strides Pharma Inc. The label states each film-coated tablet contains 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil. It indicates storage instructions, packaging of 30 tablets, and usage as prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.